Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANRO Alto Neuroscience	$2.73 -5.1%	$2.36	$1.60 ▼ $17.55	$77.70M	1.87	383,894 shs	117,411 shs
CLLS Cellectis	$1.41 -3.4%	$1.42	$1.10 ▼ $2.81	$78.37M	3.11	142,217 shs	39,491 shs
MIST Milestone Pharmaceuticals	$1.52 +7.0%	$1.16	$0.63 ▼ $2.75	$81.27M	0.86	903,440 shs	647,708 shs
NRSN NeuroSense Therapeutics	$1.58 +3.9%	$1.11	$0.51 ▼ $1.63	$21.59M	1.36	251,379 shs	129,323 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANRO Alto Neuroscience	-5.05%	-5.05%	+13.07%	-1.80%	-77.81%
CLLS Cellectis	-3.42%	-7.24%	-8.44%	+6.02%	-49.28%
MIST Milestone Pharmaceuticals	+7.04%	+10.14%	+12.59%	-12.64%	-7.88%
NRSN NeuroSense Therapeutics	+3.95%	+5.33%	+61.44%	+47.66%	+44.95%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANRO Alto Neuroscience	2.2888 of 5 stars	3.3	3.0	3.1	0.8	0.6
CLLS Cellectis	3.1388 of 5 stars	3.5	5.0	1.9	2.5	0.6
MIST Milestone Pharmaceuticals	2.641 of 5 stars	3.2	5.0	2.2	2.5	0.0
NRSN NeuroSense Therapeutics	2.0071 of 5 stars	3.5	3.0	1.9	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANRO Alto Neuroscience	2.57	Moderate Buy	$15.40	465.14% Upside
CLLS Cellectis	3.00	Buy	$6.67	372.81% Upside
MIST Milestone Pharmaceuticals	2.40	Hold	$17.00	1,018.42% Upside
NRSN NeuroSense Therapeutics	3.00	Buy	$14.00	786.08% Upside

Current Analyst Ratings Breakdown

Latest NRSN, ANRO, MIST, and CLLS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	ANRO Alto Neuroscience	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$4.00 ➝ $4.00
5/13/2025	CLLS Cellectis	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$5.00 ➝ $4.00
5/12/2025	NRSN NeuroSense Therapeutics	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/12/2025	NRSN NeuroSense Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00
4/7/2025	ANRO Alto Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00
4/1/2025	MIST Milestone Pharmaceuticals	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
4/1/2025	MIST Milestone Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/1/2025	MIST Milestone Pharmaceuticals	TD Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
3/28/2025	MIST Milestone Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00
3/21/2025	ANRO Alto Neuroscience	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
3/17/2025	MIST Milestone Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	N/A	N/A
CLLS Cellectis	$47.63M	1.65	N/A	N/A	$1.52 per share	0.93
MIST Milestone Pharmaceuticals	$1M	81.27	N/A	N/A	$0.50 per share	3.04
NRSN NeuroSense Therapeutics	N/A	N/A	N/A	N/A	($0.14) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANRO Alto Neuroscience	-$36.31M	-$2.34	N/A	N/A	N/A	N/A	-49.28%	-33.52%	8/12/2025 (Estimated)
CLLS Cellectis	-$101.06M	-$0.86	N/A	N/A	N/A	-234.39%	-74.55%	-22.65%	8/5/2025 (Estimated)
MIST Milestone Pharmaceuticals	-$59.69M	-$0.78	N/A	N/A	N/A	N/A	-151.82%	-49.85%	8/14/2025 (Estimated)
NRSN NeuroSense Therapeutics	-$11.28M	-$0.54	N/A	∞	N/A	N/A	N/A	-590.79%	6/24/2025 (Estimated)

Latest NRSN, ANRO, MIST, and CLLS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/24/2025	Q1 2025	NRSN NeuroSense Therapeutics	-$0.13	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	MIST Milestone Pharmaceuticals	-$0.19	-$0.31	-$0.12	-$0.31	N/A	N/A
5/13/2025	Q1 2025	ANRO Alto Neuroscience	-$0.59	-$0.53	+$0.06	-$0.56	N/A	N/A
5/12/2025	Q1 2025	CLLS Cellectis	-$0.1540	-$0.18	-$0.0260	-$0.18	$12.71 million	$12.03 million
4/7/2025	Q4 2024	NRSN NeuroSense Therapeutics	-$0.12	-$0.06	+$0.06	-$0.06	N/A	N/A
3/20/2025	Q4 2024	ANRO Alto Neuroscience	-$0.65	-$0.56	+$0.09	-$0.56	N/A	N/A
3/13/2025	Q4 2024	CLLS Cellectis	$0.06	-$0.16	-$0.22	-$0.15	$5.90 million	$33.22 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	N/A
CLLS Cellectis	N/A	N/A	N/A	N/A	N/A
MIST Milestone Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NRSN NeuroSense Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANRO Alto Neuroscience	0.05	13.10	13.09
CLLS Cellectis	0.48	1.78	1.78
MIST Milestone Pharmaceuticals	2.18	15.40	15.40
NRSN NeuroSense Therapeutics	N/A	0.21	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANRO Alto Neuroscience	N/A
CLLS Cellectis	63.90%
MIST Milestone Pharmaceuticals	86.18%
NRSN NeuroSense Therapeutics	1.04%

Insider Ownership

Company	Insider Ownership
ANRO Alto Neuroscience	11.13%
CLLS Cellectis	16.41%
MIST Milestone Pharmaceuticals	19.50%
NRSN NeuroSense Therapeutics	27.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANRO Alto Neuroscience	N/A	27.07 million	N/A	N/A
CLLS Cellectis	290	55.58 million	46.46 million	Optionable
MIST Milestone Pharmaceuticals	30	53.46 million	48.05 million	Optionable
NRSN NeuroSense Therapeutics	10	13.67 million	9.92 million	Not Optionable

NRSN, ANRO, MIST, and CLLS Headlines

Recent News About These Companies

Neurosense, awaiting Canada approval, scales PrimeC production

May 15, 2025 | alsnewstoday.com

D. Boral Capital Initiates Coverage of NeuroSense Therapeutics (NRSN) with Buy Recommendation

May 14, 2025 | msn.com

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights

May 12, 2025 | benzinga.com

NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch

May 7, 2025 | prnewswire.com

NeuroSense Therapeutics Advances ALS Treatment and Strategic Partnership

April 24, 2025 | tipranks.com

NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update

April 24, 2025 | prnewswire.com

NeuroSense Therapeutics Presents Promising Phase 2b Data on PrimeC for ALS at AAN Meeting

April 10, 2025 | sohu.com

NeuroSense Therapeutics Reports Year-End 2024 Financial Results and Provides Business Updates

April 10, 2025 | sohu.com

NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment

April 9, 2025 | prnewswire.com

NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates

April 7, 2025 | prnewswire.com

NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting

April 4, 2025 | prnewswire.com

Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug

March 20, 2025 | businesswire.com

NeuroSense Advances PrimeC Commercialization in Canada

March 19, 2025 | tipranks.com

PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape

March 17, 2025 | businesswire.com

Life Saving Innovation in Neurodegenerative Disease Treatment: An Interview with Alon Ben-Noon, CEO & Founder of NeuroSense Therapeutics

March 12, 2025 | techbullion.com

NeuroSense Therapeutics Reports Positive Phase 2b Study Results for ALS Treatment

February 19, 2025 | tipranks.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Elevance Health (ELV) and Genmab (GMAB)

February 4, 2025 | markets.businessinsider.com

NeuroSense regains Nasdaq compliance

January 8, 2025 | markets.businessinsider.com

Neurosense plans to license rights to advance PrimeC in certain regions

January 7, 2025 | alsnewstoday.com

NeuroSense Regains Nasdaq Compliance, Strengthens Position for ALS Treatment

January 6, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook
By Leo Miller | May 27, 2025
View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook
D-Wave Pushes Back on Short Seller Case With Strong Earnings
By Nathan Reiff | May 14, 2025
View D-Wave Pushes Back on Short Seller Case With Strong Earnings
GameStop Buys Bitcoin: Smart Strategy or Big Mistake?
By Thomas Hughes | May 28, 2025
View GameStop Buys Bitcoin: Smart Strategy or Big Mistake?
Southwest Airlines CEO Calls Recession, Why Option Traders Jumped
By Gabriel Osorio-Mazilli | April 29, 2025
View Southwest Airlines CEO Calls Recession, Why Option Traders Jumped

NRSN, ANRO, MIST, and CLLS Company Descriptions

Alto Neuroscience NYSE:ANRO

$2.72 -0.15 (-5.05%)

Closing price 05/28/2025 03:59 PM Eastern

Extended Trading

$2.72 0.00 (-0.18%)

As of 05:14 AM Eastern

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

Cellectis NASDAQ:CLLS

$1.41 -0.05 (-3.42%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$1.46 +0.05 (+3.19%)

As of 05:44 AM Eastern

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Milestone Pharmaceuticals NASDAQ:MIST

$1.52 +0.10 (+7.04%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$1.55 +0.03 (+1.97%)

As of 06:06 AM Eastern

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

NeuroSense Therapeutics NASDAQ:NRSN

$1.58 +0.06 (+3.95%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$1.57 -0.01 (-0.38%)

As of 05:40 AM Eastern

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time